Patents Assigned to Nventa Biopharmaceuticals Corporation
  • Human papilloma virus treatment
    Patent number: 7754449
    Abstract: Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: July 13, 2010
    Assignee: Nventa Biopharmaceuticals Corporation
    Inventors: John R. Neefe, Stephen E. Goldstone, Mark T. Winnett, Marvin Siegel, Leslie J. Boux
  • DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS
    Publication number: 20090041809
    Abstract: Immunostimulatory agents, including nucleic acids having one or more than one locked nucleic acid (LNA) nucleosides are provided. The nucleic acids may further comprise CpG motifs. The nucleic acids may be double stranded, and may comprise dsRNA.
    Type: Application
    Filed: March 7, 2008
    Publication date: February 12, 2009
    Applicant: NVENTA BIOPHARMACEUTICALS CORPORATION
    Inventor: Peter Emtage
  • Human papilloma virus treatment
    Patent number: 7211411
    Abstract: Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: May 1, 2007
    Assignee: Nventa Biopharmaceuticals Corporation
    Inventors: John R. Neefe, Stephen E. Goldstone, Mark T. Winnett, Marvin Siegel, Leslie J. Boux